文献速递妇科

阿什肯纳兹犹太人基于人群的BRCA检测随机试验:长期结局

Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.
PubMed 文献 · BJOG · 2019-09-10

本研究为随机对照试验,比较基于人群与基于家族史/临床标准的BRCA检测对心理健康和生活质量的长期影响。共1034名阿什肯纳兹犹太人随机分入人群筛查组(530人)和家族史/临床标准组(504人),随访3年。结果显示人群筛查组焦虑和焦虑-抑郁总分较家族史组显著降低,其他心理及生活质量指标无显著差异,且可识别更多BRCA携带者。

要点

  • 人群筛查组较家族史组焦虑评分(P=0.046)和焦虑-抑郁总分(P=0.012)显著降低。
  • 两组抑郁、健康焦虑、痛苦、不确定性、生活质量或体验评分无显著差异。
  • 30名BRCA携带者中18名(60%)不符合临床标准,总BRCA患病率2.9%。

核心结论

  • 基于人群的阿什肯纳兹犹太人BRCA检测不损害长期心理健康或生活质量,降低焦虑,并可识别最多150%额外的BRCA携带者。

研究设计与样本

  • 随机对照试验(ISRCTN73338115)GCaPPS,两臂:人群筛查组和家族史/临床标准组,1:1随机。
  • 共1034人(691名女性,343名男性)随机分入人群筛查组(n=530)或家族史组(n=504)。
  • 纳入标准:阿什肯纳兹犹太人女性/男性>18岁;排除标准:既往BRCA检测或BRCA携带者的一级亲属。
  • 检测三种犹太BRCA founder突变:185delAG(c.68_69delAG)、5382insC(c.5266dupC)和6174delT(c.5946delT)。
  • 使用线性混合模型和对比检验分析BRCA检测对心理和生活质量结局的影响,随访3年。

主要发现

  • 人群筛查组较家族史组3年内焦虑评分显著降低(P=0.046),焦虑-抑郁总分显著降低(P=0.012)。
  • 家族史组与人群筛查组在抑郁、健康焦虑、痛苦、不确定性、生活质量或BRCA检测相关体验评分方面无显著差异。
  • 对比检验显示人群筛查组和家族史组随时间推移焦虑评分(P=0.018)、健康焦虑评分(P<0.0005)和生活质量评分(P=0.004)均降低。
  • 30名BRCA携带者中18名(60%)不符合BRCA检测的临床标准。
  • 总BRCA患病率2.9%(95%CI 1.97-4.12%),BRCA1患病率1.55%(95%CI 0.89-2.5%),BRCA2患病率1.35%(95%CI 0.74-2.26%)。

关键数值与推荐

  • 使用经验证问卷(HADS/MICRA/HAI/SF12)分析基线、1年、2年和3年随访时的心理健康/生活质量结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Unselected population-based BRCA testing provides the opportunity to apply genomics on a population-scale to maximise primary prevention for breast-and-ovarian cancer. We compare long-term outcomes of population-based and family-history (FH)/clinical-criteria-based BRCA testing on psychological health and quality of life. DESIGN: Randomised controlled trial (RCT) (ISRCTN73338115) GCaPPS, with two-arms: (i) population-screening (PS); (ii) FH/clinical-criteria-based testing. SETTING: North London Ashkenazi-Jewish (AJ) population. POPULATION/SAMPLE: AJ women/men. METHODS: Population-based RCT (1:1). Participants were recruited through self-referral, following pre-test genetic counselling from the North London AJ population. INCLUSION CRITERIA: AJ women/men >18 years old; exclusion-criteria: prior BRCA testing or first-degree relatives of BRCA-carriers. INTERVENTIONS: Genetic testing for three Jewish BRCA founder-mutations: 185delAG (c.68_69delAG), 5382insC (c.5266dupC) and 6174delT (c.5946delT), for (i) all participants in PS arm; (ii) those fulfilling FH/clinical criteria in FH arm. Linear mixed models and appropriate contrast tests were used to analyse the impact of BRCA testing on psychological and quality-of-life outcomes over 3 years. MAIN OUTCOME MEASURES: Validated questionnaires (HADS/MICRA/HAI/SF12) used to analyse psychological wellbeing/quality-of-life outcomes at baseline/1-year/2-year/3-year follow up. RESULTS: In all, 1034 individuals (691 women, 343 men) were randomised to PS (n = 530) or FH (n = 504) arms. There was a statistically significant decrease in anxiety (P = 0.046) and total anxiety-&-depression scores (P = 0.0.012) in the PS arm compared with the FH arm over 3 years. No significant difference was observed between the FH and PS arms for depression, health-anxiety, distress, uncertainty, quality-of-life or experience scores associated with BRCA testing. Contrast tests showed a decrease in anxiety (P = 0.018), health-anxiety (P < 0.0005) and quality-of-life (P = 0.004) scores in both PS and FH groups over time. Eighteen of 30 (60%) BRCA carriers identified did not fulfil clinical criteria for BRCA testing. Total BRCA prevalence was 2.9% (95% CI 1.97-4.12%), BRCA1 prevalence was 1.55% (95% CI 0.89-2.5%) and BRCA2 prevalence was 1.35% (95% CI 0.74-2.26%). CONCLUSION: Population-based AJ BRCA testing does not adversely affect long-term psychological wellbeing or quality-of-life, decreases anxiety and could identify up to 150% additional BRCA carriers. TWEETABLE ABSTRACT: Population BRCA testing in Ashkenazi Jews reduces anxiety and does not adversely affect psychological health or quality of life.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Manchanda R, Burnell M, Gaba F, et al. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes. BJOG. 2019. PMID: 31507061. doi:10.1111/1471-0528.15905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。